Searchable abstracts of presentations at key conferences in endocrinology

ea0089c19 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2022

Transformation of G1-G2 Neuroendocrine Tumors (NETs) to Neuroendocrine Carcinomas (NECs) Following Peptide Receptor Radionuclide Therapy (PRRT): a Case Series

Cordero-Hernandez Igryl S. , Ross Alicia C. , Dasari Arvind , Halperin Daniel M. , Chasen Beth , Yao James C.

Background: We observed patients with well-differentiated NETs who received PRRT with 177Lu-dotatate and later developed rapid disease progression with biopsy-proven histologic transformation to NECs, an outcome that has not been previously described. In this series, we characterize the clinicopathologic features and outcomes of patients whose tumors underwent poorly-differentiated transformation.Methods: After obtaining IRB approval, we condu...

ea0098t11 | Trials In Progress | NANETS2023

NET RETREAT: a Phase II Study of 177Lutetium-Dotatate Retreatment vs. Everolimus in Metastatic/Unresectable Midgut NET

Chauhan Aman , O'Callaghan Chris , Myrehaug Sten , Bodei Lisa , Kunz Pamela , Dasari Arvind , Strosberg Jonathan , Alexander Stefanie , Cheung Winson , Singh Simron

Background: 177Lu-DOTATATE is an FDA and Health Canada-approved treatment option for metastatic, progressive GEPNET patients. 177Lu-DOTATATE is now often considered the treatment of choice for small bowel/midgut patients who have progressed on somatostatin analogs (SSA). Despite 177Lu- DOTATATE’s impressive disease stabilization, many patients will eventually progress. Progression after prior use of PRRT does not necessarily render these tumors resistant to future PRRT tr...

ea0089o1 | Other | NANETS2022

Efficacy and Toxicity of Anti-Vascular Endothelial Growth Factor (VEGF) Receptor Tyrosine Kinase Inhibitors (TKIs) in Neuroendocrine Tumors (NETs) – A Systematic Review and Meta-Analysis

Das, MD, MSCI Satya , Phillips, MSPH Sharon , M Lebeck Lee, MD Cody , Agarwal, MD, MSCI Rajiv , Bergsland, MD Emily , Strosberg, MD Jonathan , A. Chan, MD, MPH Jennifer , LaFerriere, MLIS Heather , A. Ramirez, DO Robert , Berlin, MD Jordan , Arvind Dasari, MD, MS and

Background: Although anti-VEGF RTKIs have been tested in patients with NETs over the last 2 decades, no study to date has benchmarked efficacy and toxicity of these drugs in this patient population.Methods: A literature search was performed to identify all phase II and phase III studies of anti-VEGF RTKIs in patients with NETs published between January 1, 2000 – July 31, 2021. Major trial databases (e.g. Medline, EMBASE, Cumulative Index of Nursing ...

ea0098o2 | Other | NANETS2023

Germline testing identifies pathogenic/likely pathogenic variants in patients with pancreatic neuroendocrine tumors

Mohindroo Chirayu , Baydogan Seyda , Agarwal Parul , Laheru Dan , Wright Robin , Prakash Laura R. , Mork Maureen E. , Klein Alison P. , Maxwell Jess , H.G. Katz Matthew , Dasari Arvind , Kim Michael P. , He Jin , McAllister Florencia , De Jesus-Acosta Ana

Background: 10% of pancreatic neuroendocrine tumors (pNETs) are thought to be related to inherited syndromes, (MEN1, MEN4, VHL, NF1 and TSC). Growing evidence suggests, that clinically sporadic appearing pNETs can harbor germline mutations. Here, we report the prevalence of pathological/likely pathological germline variants (P/LP) in 2 cohorts: 1) High-risk and 2) Unselected.Methods: We retrospectively collected clinical data of pNET patients seen at MD ...